HC
Hutchison China Meditech Ltd Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Edith Shih, was filed 21 Mar 2016.
Hutchison China Meditech Ltd: what insiders have been doing
Only a handful of insider records exist for Hutchison China Meditech Ltd, the last one from 21 March 2016, too few to describe a trend. This summary is built from RNS (LSE) disclosures alone and does not predict where the share price will go.
Insider Decl.
1
Thresholds
n/a
Buy Volume
€490,246
1 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
US$14.74
Analyst consensus
Income statement
EBITDA-US$20.5M
Valuation
P/Book2.0x
Beta0.36
Balance sheet & cash
Debt / Equity7%
Profitability & ownership
ROE1.5%
ROA-1.2%
% insiders0.0%
% institutions2.6%
Last declaration on 21 March 2016
Declarations1 total
- 40,741 shares@ US$13.50100.0% of flowFCA-NSM:LSE20160321085451_012745306_20200330143607009_16661Canonical exit: 15 Jun 2016 (T+90)
1 of 1 declaration
About Hutchison China Meditech Ltd
Hutchison China Meditech Ltd is a biopharmaceutical company focused on the development and commercialization of drugs in China and internationally. It is listed on the London Stock Exchange.
